Lévy Pierre - CV

Articles

Fauchier L., Lamblin N., Tardu J., Bellier L., Groyer H., Ittah D., Chollet J., Linden P., Lévy P. (2023), Public Health Impact and Cost-Effectiveness of Empagliflozin (JARDIANCE®) in the Treatment of Patients with Heart Failure with Preserved Ejection Fraction in France, Based on the EMPEROR-Preserved Clinical Trial, PharmacoEconomics - Open, vol. 8, p. 19-30

Kirchhof P., Pecen L., Bakhai A., de Asmundis C., de Groot J., Deharo J., Kelly P., Lévy P., López-de-Sá E., Monteiro P., Steffel J., Waltenberger J., Weiss T., Laeis P., Manu M., Souza J., De Caterina R. (2022), Edoxaban for stroke prevention in atrial fibrillation and age-adjusted predictors of clinical outcomes in routine clinical care, European Heart Journal - Cardiovascular Pharmacotherapy, vol. 9, n°1, p. 47-57

Pochopień M., Cherney D., Drzewiecka A., Folkerts ., Lévy P., Millier A., Morris ., Palarczyk M., Roy-Chaudhury ., Sullivan ., Mernagh . (2022), Validation of the FINE-CKD model for future health technology assessments for finerenone in patients with chronic kidney disease and type 2 diabetes, American Journal of Managed Care, vol. 28, n°Suppl 6, p. S104-S111

Pathak A., Lévy P., Roubille F., Chatellier G., Mercier G., Alami S., Lancman G., Pasche H., Laurelli C., Delval C., Ramirez-Gil J., Galinier M. (2022), Healthcare costs of a telemonitoring programme for heart failure: indirect deterministic data linkage analysis, ESC Heart Failure, vol. 9, n°6, p. 3888-3897

Pochopień M., Cherney D., Folkerts ., Lévy P., Millier A., Morris ., Roy-Chaudhury ., Sullivan ., Mernagh . (2021), FINE-CKD Model to Evaluate Economic Value of Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes, American Journal of Managed Care, vol. 27, n°20, p. S375-S382

Mehran R., Vogel B., Lévy P. (2021), Reducing the cost of managing patients with atrial fibrillation undergoing percutaneous coronary intervention with stenting, Journal of Cardiology, vol. 77, n°1, p. 93-99

de Groot J., Weiss T., Kelly P., Monteiro P., Deharo J., de Asmundis C., Esteban López-de-Sá ., Waltenberger J., Steffel J., Lévy P., Bakhai A., Zierhut W., Laeis P., Manu M., Reimitz P-E., De Caterina R., Kirchhof P. (2021), Edoxaban for stroke prevention in atrial fibrillation in routine clinical care: 1-year follow-up of the prospective observational ETNA-AF-Europe study, European Heart Journal - Cardiovascular Pharmacotherapy, vol. 7, n°FI1, p. f30-f39

Ferrier C., Thébaut C., Lévy P., Baffert S., Asselain B., Rouzier R., Hequet D. (2021), Absenteeism and indirect costs during the year following the diagnosis of an operable breast cancer: A prospective multicentric cohort study, Journal of Gynecology Obstetrics and Human Reproduction, vol. 50, n°6, p. 101871

Christensen H., Al-Janabi H., Lévy P., Postma M., Bloom D., Landa P., Damm O., Salisbury ., Diez-Domingo J., Towse A., Lorgelly P., Shah ., Hernandez-Villafuerte K., Smith V., Glennie L., Wright C., York ., Farkouh R. (2020), Economic evaluation of meningococcal vaccines: considerations for the future, The European Journal of Health Economics, vol. 21, p. 297-309

Cohen A., Hoffmann U., Hainaut P., Gaine S., Ay C., Coppens M., Schindewolf M., Jiménez D., Brüggenjürgen B., Lévy P., Laeis P., Fronk E-M., Zierhut W., Malzer T., Manu M., Reimitz P-E., Bramlage P., Agnelli G. (2020), ETNA VTE Europe: A contemporary snapshot of patients treated with edoxaban in clinical practice across eight European countries, European Journal of Internal Medicine, vol. 82, p. 48-55

Bowrin K., Briere J-B., Lévy P., Millier A., Tardu J., Toumi M. (2020), Real-world cost-effectiveness of rivaroxaban and apixaban vs VKA in stroke prevention in non-valvular atrial fibrillation in the UK, Journal of Market Access & Health Policy, vol. 8, n°1, p. 1782164

Ferrier C., Thébaut C., Lévy P., Baffert S., Asselain B., Rouzier R., Hequet D. (2020), Absenteeism and indirect costs during the year following the diagnosis of an operable breast cancer: A prospective multicentric cohort study, Journal of Gynecology Obstetrics and Human Reproduction, p. 101871

Bowrin K., Briere J-B., Lévy P., Toumi M., Millier A. (2020), Use of real-world evidence in meta-analyses and cost-effectiveness models, Journal of Medical Economics, vol. 23, n°10, p. 1053-1060

Donnet A., Emery C., Aly S., Allaf B., Cayre F., Mahieu N., Gourmelen J., Lévy P., Fagnani F. (2019), Migraine burden and costs in France: a nationwide claims database analysis of triptan users, Journal of Medical Economics, vol. 22, n°7, p. 616-624

Lévy P., Smadja D., Dorey J., Toumi M., Meinecke A-K., Bowrin K., Briere J-B. (2019), Estimation of the costs attributable to vitamin K antagonist treatment in patients with non-valvular atrial fibrillation from a French societal perspective, Journal of Market Access & Health Policy, vol. 7, n°1, p. 1564506

Coleman C., Briere J-B., Fauchier L., Lévy P., Bowrin K., Toumi M., Millier A., Taieb V., Wu O. (2019), Meta-analysis of real-world evidence comparing non-vitamin K antagonist oral anticoagulants with vitamin K antagonists for the treatment of patients with non-valvular atrial fibrillation, Journal of Market Access & Health Policy, vol. 7, n°1, p. 1574541

Briere J-B., Wu O., Bowrin K., Millier A., Toumi M., Taieb V., Lévy P., Coleman C. (2019), Impact of methodological choices on a meta-analysis of real-world evidence comparing non-vitamin K antagonist oral anticoagulants with vitamin K antagonists for the treatment of patients with non-valvular atrial fibrillation, Current Medical Research and Opinion, p. 1-1

Bowrin K., Briere J-B., Lévy P., Millier A., Clay E., Toumi M. (2019), Cost-effectiveness analyses using real-world data: an overview of the literature, Journal of Medical Economics, vol. 22, n°6, p. 545-553

Chouaid C., Bensimon L., Clay E., Millier A., Levy-Bachelot L., Huang M., Lévy P. (2019), Cost-effectiveness analysis of pembrolizumab versus standard-of-care chemotherapy for first-line treatment of PD-L1 positive (>50%) metastatic squamous and non-squamous non-small cell lung cancer in France, Lung Cancer, vol. 127, p. 44-52

De Caterina R., Kelly P., Monteiro P., Deharo J., de Asmundis C., López-de-Sá E., Weiss T., Waltenberger J., Steffel J., de Groot J., Bakhai A., Zierhut W., Lévy P., Laeis P., Reimitz P-E., Kirchhof P. (2019), Design and rationale of the Edoxaban Treatment in routiNe clinical prActice for patients with Atrial Fibrillation in Europe (ETNA-AF-Europe) study, Journal of Cardiovascular Medicine, vol. 20, n°2, p. 97-104

Claudepierre P., Lahfa M., Lévy P., Barnetche T., Bonnet I., Aubert R., Roquelaure Y. (2018), The impact of psoriasis on professional life: PsoPRO, a French national survey, Journal of the European Academy of Dermatology and Venereology (JEADV) , vol. 32, n°10, p. 1702-1709

Paix A., Noel G., Falcoz P-E., Lévy P. (2018), Cost-effectiveness analysis of stereotactic body radiotherapy and surgery for medically operable early stage non small cell lung cancer, Radiotherapy and Oncology, vol. 128, n°3, p. 534-540

Dunlop W., Staufer A., Lévy P., Edwards G. (2018), Innovative pharmaceutical pricing agreements in five European markets: A survey of stakeholder attitudes and experience, Health Policy, vol. 122, n°5, p. 528-532

Cohen A., Ay C., Hainaut P., Décousus H., Hoffmann U., Gaine S., Coppens M., da Silva P., Jiménez D., Amann-Vesti B., Brüggenjürgen B., Lévy P., Bastida J., Vicaut E., Laeis P., Fronk E-M., Zierhut W., Malzer T., Bramlage P., Agnelli G. (2018), Design and rationale of the non-interventional, edoxaban treatment in routiNe clinical prActice in patients with venous ThromboEmbolism in Europe (ETNA-VTE-Europe) study, Thrombosis Journal, vol. 16, n°1

Cheung K., Evers S., De Vries H., Lévy P., Pokhrel S., Jones T., Danner M., Wentlandt J., Knufinke L., Mayer S., Hiligsmann M. (2017), Most important barriers and facilitators of HTA usage in decision-making in Europe, Expert Review of Pharmacoeconomics & Outcomes Research, vol. 18, n°3, p. 297-304

Friedmann C., Lévy P., Hensel P., Hiligsmann M. (2017), Using multi-criteria decision analysis to appraise orphan drugs: a systematic review, Expert Review of Pharmacoeconomics & Outcomes Research

Druais S., Doutriaux A., Cognet M., Godet A., Lançon C., Lévy P., Samalin L., Guillon P. (2016), Cost Effectiveness of Paliperidone Long-Acting Injectable Versus Other Antipsychotics for the Maintenance Treatment of Schizophrenia in France, PharmacoEconomics, vol. 34, n°4, p. 363-391

Kaucley L., Levy P. (2015), Cost-effectiveness analysis of routine immunization and supplementary immunization activity for measles in a health district of Benin, Cost Effectiveness and Resource Allocation, vol. 13

Mennini F., Marcellusi A., Graf von der Schulenburg J., Gray A., Lévy P., Sciattella, P., Soro M., Staffiero G., Zeidler J., Maggioni A., Schmieder R. (2015), Cost of poor adherence to anti-hypertensive therapy in five European countries, The European Journal of Health Economics, vol. 16, n°1, p. 65-72

Largeron N., Levy P., Wasem J., Bresse X. (2015), Role of vaccination in the sustainability of healthcare systems, Journal of Market Access & Health Policy, vol. 3, p. 8

Doutriaux A., Cognet M., Druais S., Lançon C., Samalin L., Lévy P., Godet A., Guillon P. (2014), PMH35 – Cost-Effectiveness of Paliperidone Palmitate Versus other Antipsychotics for the Treatment of Schizophrenia in France, Value in Health, vol. 17, n°7, p. A459–A460

Abotsi A., Inkoom E., Ribaira E., Le Mentec R., Lévy P., Lafarge H., de Sousa A. (2012), Cost Effectiveness of Intermittent Preventive Treatment of Malaria in Infants in Ghana, International Journal of Tropical Disease & Health, vol. 2, n°1, p. 1-15

Lévy P., Ebong C. (2011), Impact of the introduction of new vaccines and vaccine wastage rate on the cost-effectiveness of routine EPI: lessons from a descriptive study in a Cameroonian health district, Cost Effectiveness and Resource Allocation, vol. 9, n°9

Beauté J., Lévy P., Millet V., Debré M., Dudoit Y., Le Mignot L., Tajahmady A., Thomas C., Suarez F., Pellier I., Hermine O., Aladjidi N., Mahlaoui N., Fischer A. (2010), Economic evaluation of immunoglobulin replacement in patients with primary antibody deficiencies, Clinical and Experimental Immunology, vol. 160, n°2, p. 240-245

Lévy P. (2008), L’analyse d’impact budgétaire et l’évaluation économique : des approches substituables ou complémentaires?, La Lettre du Collège, vol. 19ème année, n°4, p. 4-6

Lévy P., Fried M., Santini F., Finer N. (2007), The Comparative Effects of Bariatric Surgery on Weight and Type 2 Diabetes, Obesity Surgery, vol. 17, n°9, p. 1248-1256

Lévy P. (2002), Economic Evaluation of Antiepileptic Drug Therapy: A Methodologic Review, Epilepsia, vol. 43, n°5, p. 550-558

Lévy P., Lévy E. (2002), Pharmacoeconomic Considerations in Assessing and Selecting Congestive Heart Failure Therapies, PharmacoEconomics, vol. 20, n°14, p. 963-977

Lévy E., Lévy P. (1993), Treatment of peritonitis in France: Comparative cost-effectiveness of the association imipenem-cilastatin and other antibiotic therapy, Journal de chirurgie, vol. 130, n°4, p. 200-209

Chapitres d'ouvrage

Lévy P. (2005), L’évaluation économique des maladies chroniques, in Wittwer, Jérôme, Economie du vieillissement : âge et protection sociale (tome 2), Paris: L'Harmattan, p. 263-282

Communications sans actes

Lévy P. (2009), Pharmaco-économie et analyse d’impact budgétaire : les recommandations du CES, 4ème Séminaire scientifique de pharmaco-épidémiologie, Paris, France

Lévy P. (2005), Viabilité financière et efficience des stratégies vaccinales dans les pays en développement : des approches substituables ou complémentaires ? Une réponse fondée sur la littérature grise, Financement de la santé dans les pays en développement, 2e colloque CERDI (Centre d'Etudes et de Recherches sur le Développement International), Clermont-Ferrand, France

Rapports

Lévy P., de Kervasdoué J. (2007), Nutrition et économie de la santé

Fermon B., Lévy P. (2006), Les modalités d’utilisation des indicateurs de qualité par les différents acteurs du système de santé et leurs impacts potentiels – Etude bibliographique

Fermon B., Lévy P. (2005), La diffusion publique de données relatives à l’activité, la performance, les résultats des établissements de santé – Etude bibliographique, 68 p.

Lévy P., Lévy E. (2002), L’extension de la prise en charge du vaccin anti-grippal aux adultes actifs, 61 p.